Huyu Wang1, Lili Shui2, Yajuan Chen3,4. 1. Department of Chongqing Medical University, Chongqing, 400016, China. 2. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. 3. Department of Chongqing Medical University, Chongqing, 400016, China. yajuanchencqmu@sina.com. 4. Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. yajuanchencqmu@sina.com.
Abstract
OBJECTIVE: To determine whether the combined use of glucocorticoid with other immunosuppressants increased the risk of Pneumocystis jirovecii pneumonia (PCP) in autoimmune inflammatory disease (AIID) patients. METHODS: The data were collected from the PubMed, Cochrane Library, and Web of Science databases. We excluded HIV-infected patients and those < 16 years of age, and included patients who combined use of glucocorticoid with other immunosuppressants or used glucocorticoid alone. The number of patients who were affected by PCP after therapy as the primary outcome and the number of patients with fatal outcomes, which included death, endotracheal tube intubation, PO2 < 60 mmHg, and other serious clinical symptoms due to PCP, as the secondary outcome. Odds ratios with 95% confidence intervals and variance tests were used to analyze the data. RESULTS: The outcomes showed that the combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients (odds ratio = 2.85, 95% confidence intervals 1.75 to 4.64, I2 = 0%, P < 0.0001), which may be a consequence of the drug regimen reducing the lymphocyte count. Furthermore, the prognosis of patients receiving this drug regimen was poorer than with glucocorticoid alone (odds ratio = 2.31, 95% confidence intervals 1.02 to 5.23, I2 = 0%, P = 0.04). CONCLUSION: The combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients and resulted in poorer prognoses. It is therefore clear that appropriate prophylaxis was vital in AIID patients to minimize the risk of PCP. Key Points • We demonstrated that the combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients and resulted in poorer prognoses. • As there are no standard prophylactic guidelines, we wish this work will be evidence to guide clinical prophylaxis.
OBJECTIVE: To determine whether the combined use of glucocorticoid with other immunosuppressants increased the risk of Pneumocystis jirovecii pneumonia (PCP) in autoimmune inflammatory disease (AIID) patients. METHODS: The data were collected from the PubMed, Cochrane Library, and Web of Science databases. We excluded HIV-infected patients and those < 16 years of age, and included patients who combined use of glucocorticoid with other immunosuppressants or used glucocorticoid alone. The number of patients who were affected by PCP after therapy as the primary outcome and the number of patients with fatal outcomes, which included death, endotracheal tube intubation, PO2 < 60 mmHg, and other serious clinical symptoms due to PCP, as the secondary outcome. Odds ratios with 95% confidence intervals and variance tests were used to analyze the data. RESULTS: The outcomes showed that the combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients (odds ratio = 2.85, 95% confidence intervals 1.75 to 4.64, I2 = 0%, P < 0.0001), which may be a consequence of the drug regimen reducing the lymphocyte count. Furthermore, the prognosis of patients receiving this drug regimen was poorer than with glucocorticoid alone (odds ratio = 2.31, 95% confidence intervals 1.02 to 5.23, I2 = 0%, P = 0.04). CONCLUSION: The combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients and resulted in poorer prognoses. It is therefore clear that appropriate prophylaxis was vital in AIID patients to minimize the risk of PCP. Key Points • We demonstrated that the combined use of glucocorticoid with other immunosuppressants increased the risk of PCP in AIID patients and resulted in poorer prognoses. • As there are no standard prophylactic guidelines, we wish this work will be evidence to guide clinical prophylaxis.
Authors: F Roblot; C Godet; G Le Moal; B Garo; M Faouzi Souala; M Dary; L De Gentile; J A Gandji; Y Guimard; C Lacroix; P Roblot; B Becq-Giraudon Journal: Eur J Clin Microbiol Infect Dis Date: 2002-07-13 Impact factor: 3.267
Authors: Cornelia M Spies; Cindy Strehl; Marlies C van der Goes; Johannes W J Bijlsma; Frank Buttgereit Journal: Best Pract Res Clin Rheumatol Date: 2011-12 Impact factor: 4.098
Authors: Soo Jung Kim; Jinwoo Lee; Young-Jae Cho; Young Sik Park; Chang-Hoon Lee; Ho Il Yoon; Sang-Min Lee; Jae-Joon Yim; Jae Ho Lee; Chul-Gyu Yoo; Choon-Taek Lee; Young Whan Kim; Sung Koo Han; Hong Bin Kim; Jong Sun Park Journal: J Infect Date: 2014-03-04 Impact factor: 6.072
Authors: T Glück; H F Geerdes-Fenge; R H Straub; M Raffenberg; B Lang; H Lode; J Schölmerich Journal: Infection Date: 2000 Jul-Aug Impact factor: 3.553